The earnings call highlighted strong financial and commercial performance, particularly for FILSPARI in IgA nephropathy, and positive clinical data supporting its efficacy. Strategic advancements in expanding FILSPARI's indications and robust pipeline development were emphasized. However, increased SG&A expenses and potential generic competition for THIOLA products were noted as challenges. Overall, the positive developments surpassed the lowlights.

Company Guidance

In the Travere Therapeutics Second Quarter 2025 Financial Results Conference Call, significant metrics underscored the company's robust performance and strategic progress. FILSPARI, their key product, achieved net product sales of approximately $72 million in the U.S., marking strong year-over-year growth. The company reported total Q2 revenue of $114.4 million, including $19.6 million from license and collaboration, driven in part by a $17.5 million milestone payment from CSL Vifor. Their financial strength is further supported by a cash balance of approximately $319.5 million as of June 30, 2025. The company experienced an approximately 82% increase in net product sales compared to the same period last year. With a non-GAAP adjusted net income of $11.9 million, Travere is poised for sustained growth, driven by FILSPARI's expanding market presence and potential regulatory milestones for its application in FSGS, with a PDUFA date set for January 13, 2026.

Strong Performance in IgA Nephropathy

FILSPARI delivered the strongest commercial quarter to date with $72 million in net product sales in the U.S., representing significant year-over-year growth. There was a 43% increase in new patient start forms compared to the same period last year.

Positive Clinical Data for FILSPARI

In the Phase II SPARTAN trial, FILSPARI-treated patients achieved approximately 70% proteinuria reduction, with nearly 60% reaching complete proteinuria remission and stable eGFR through 24 weeks.

Financial Growth and Milestone Achievement

Net product sales grew approximately 82% over the same period last year to $94.8 million. A $17.5 million milestone payment was received from CSL Vifor following full approval in Europe.

Strategic Pipeline Advancements

Preparations are underway for the potential expansion of FILSPARI into FSGS, with an sNDA review process for a second indication advancing as expected.

Travere Therapeutics (TVTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TVTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.27 / -	-0.7	―	―	―
Aug 06, 2025	2025 (Q2)	-0.31 / -0.14	-0.91	84.62% (+0.77)	―
May 01, 2025	2025 (Q1)	-0.57 / -0.47	-1.76	73.30% (+1.29)	―
Feb 20, 2025	2024 (Q4)	-0.56 / -0.73	-1.18	38.14% (+0.45)	―
Oct 31, 2024	2024 (Q3)	-0.67 / -0.70	1.97	-135.53% (-2.67)	―
Aug 01, 2024	2024 (Q2)	-0.79 / -0.91	-1.13	19.47% (+0.22)	―
May 06, 2024	2024 (Q1)	-0.96 / -1.76	-1.27	-38.58% (-0.49)	―
Feb 15, 2024	2023 (Q4)	-1.16 / -1.18	-1.03	-14.56% (-0.15)	―
Nov 07, 2023	2023 (Q3)	-1.06 / 1.97	-1.09	280.73% (+3.06)	―
Aug 03, 2023	2023 (Q2)	-1.09 / -1.13	-1.05	-7.62% (-0.08)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TVTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$17.24	$16.91	-1.91%
May 01, 2025	$20.76	$21.15	+1.88%
Feb 20, 2025	$23.58	$21.98	-6.79%
Oct 31, 2024	$17.76	$17.50	-1.46%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Travere Therapeutics, Inc. (TVTX) report earnings?

Travere Therapeutics, Inc. (TVTX) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Travere Therapeutics, Inc. (TVTX) earnings time?

Travere Therapeutics, Inc. (TVTX) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TVTX EPS forecast?

TVTX EPS forecast for the fiscal quarter 2025 (Q3) is -0.27.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing